| Nome |
# |
|
Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells, file e309ade2-a7ce-3969-e053-3a05fe0a2c94
|
1.333
|
|
Solid tumors, file e309ade2-995d-3969-e053-3a05fe0a2c94
|
1.050
|
|
Post-thaw viability of cryopreserved peripheral blood stem cells: what are we actually looking at?, file e309ade2-9bba-3969-e053-3a05fe0a2c94
|
1.045
|
|
Novel Applications for the Flow Cytometry, file e309ade2-93c8-3969-e053-3a05fe0a2c94
|
1.022
|
|
Move on air: Webinar for education in stem cells mobilization Report I, file e309ade2-941b-3969-e053-3a05fe0a2c94
|
1.010
|
|
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2015, file e309ade2-8d80-3969-e053-3a05fe0a2c94
|
228
|
|
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib, file e309ade2-9ad6-3969-e053-3a05fe0a2c94
|
225
|
|
Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma, file e309ade2-852a-3969-e053-3a05fe0a2c94
|
168
|
|
Predictive value of hematological and phenotypical parameters on postchemotherapy leukocyte recovery, file e309ade2-9ad0-3969-e053-3a05fe0a2c94
|
150
|
|
A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs, file e309ade0-494c-3969-e053-3a05fe0a2c94
|
146
|
|
Issue Highlights-January 2013, file e309ade2-7c9f-3969-e053-3a05fe0a2c94
|
146
|
|
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia, file e309ade2-86b5-3969-e053-3a05fe0a2c94
|
142
|
|
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia, file e309ade2-8511-3969-e053-3a05fe0a2c94
|
139
|
|
Identification of Chlamydia trachomatis in a patient with ocular lymphoma, file e309ade2-353a-3969-e053-3a05fe0a2c94
|
127
|
|
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: A position statement from the European Group for Blood and Marrow Transplantation, file e309ade2-8537-3969-e053-3a05fe0a2c94
|
121
|
|
Essential requirements for setting up a stem cell processing laboratory, file e309ade2-8e30-3969-e053-3a05fe0a2c94
|
120
|
|
European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization, file e309ade2-7c98-3969-e053-3a05fe0a2c94
|
103
|
|
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial, file e309ade2-850f-3969-e053-3a05fe0a2c94
|
101
|
|
Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: A 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT), file e309ade2-86be-3969-e053-3a05fe0a2c94
|
97
|
|
Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML, file e309ade2-9505-3969-e053-3a05fe0a2c94
|
88
|
|
CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral
blood of patients affected by systemic sclerosis, file e309ade2-8f1d-3969-e053-3a05fe0a2c94
|
87
|
|
Flow Cytometry Immunophenotyping for the Evaluation of Bone Marrow Dysplasia, file e309ade4-3c54-3969-e053-3a05fe0a2c94
|
87
|
|
Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders, file e309ade0-4958-3969-e053-3a05fe0a2c94
|
86
|
|
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation, file e309ade0-c539-3969-e053-3a05fe0a2c94
|
86
|
|
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia, file e309ade2-d1d9-3969-e053-3a05fe0a2c94
|
72
|
|
Cellule mesenchimali stromali: caratterizzazione immunofenotipica e funzionale, file e309ade4-4660-3969-e053-3a05fe0a2c94
|
71
|
|
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT), file e309ade2-83a2-3969-e053-3a05fe0a2c94
|
70
|
|
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), file e309ade4-2d3b-3969-e053-3a05fe0a2c94
|
68
|
|
Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: A study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party, file e309ade2-835f-3969-e053-3a05fe0a2c94
|
66
|
|
Differences among young adults, adults and elderly chronic myeloid leukemia patients, file e309ade2-c42d-3969-e053-3a05fe0a2c94
|
65
|
|
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status, file e309ade0-b7c3-3969-e053-3a05fe0a2c94
|
63
|
|
Studio dei progenitori emopoietici circolanti in pazienti con infarto del miocardio, file e309ade4-1a6a-3969-e053-3a05fe0a2c94
|
62
|
|
Hematopoietic stem cell transplantation in Europe 2014: More than 40 000 transplants annually, file e309ade2-83a6-3969-e053-3a05fe0a2c94
|
61
|
|
Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical is improved when hematopoietic SCT is performed in a Jacie accredited program, file e309ade2-87fa-3969-e053-3a05fe0a2c94
|
61
|
|
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study, file e309ade4-679a-3969-e053-3a05fe0a2c94
|
61
|
|
Development of adaptive immune effector therapies in solid tumors, file e309ade2-88f5-3969-e053-3a05fe0a2c94
|
60
|
|
Hematopoietic SCT in Europe 2013: Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants, file e309ade2-d189-3969-e053-3a05fe0a2c94
|
60
|
|
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach, file e309ade2-8859-3969-e053-3a05fe0a2c94
|
59
|
|
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a, file e309ade4-0fae-3969-e053-3a05fe0a2c94
|
58
|
|
Hematopoietic SCT in Europe: Data and trends in 2012 with special consideration of pediatric transplantation, file e309ade2-8426-3969-e053-3a05fe0a2c94
|
57
|
|
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach, file e309ade2-c9ae-3969-e053-3a05fe0a2c94
|
56
|
|
Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike, file e309ade4-210b-3969-e053-3a05fe0a2c94
|
56
|
|
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi, file e309ade2-8c0e-3969-e053-3a05fe0a2c94
|
55
|
|
Use of haploidentical stem cell transplantation continues to increase: The 2015 European Society for Blood and Marrow Transplant activity survey report, file e309ade2-8676-3969-e053-3a05fe0a2c94
|
54
|
|
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model, file e309ade2-f303-3969-e053-3a05fe0a2c94
|
54
|
|
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia, file e309ade4-62d5-3969-e053-3a05fe0a2c94
|
54
|
|
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide, file e309ade2-81c3-3969-e053-3a05fe0a2c94
|
53
|
|
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), file e309ade2-8482-3969-e053-3a05fe0a2c94
|
53
|
|
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo, file e309ade2-8914-3969-e053-3a05fe0a2c94
|
53
|
|
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, file e309ade2-8682-3969-e053-3a05fe0a2c94
|
52
|
|
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: A retrospective study from the European Society for Blood and Marrow Transplantation database, file e309ade2-876c-3969-e053-3a05fe0a2c94
|
52
|
|
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study, file e309ade2-b708-3969-e053-3a05fe0a2c94
|
52
|
|
Issue Highlight 2015, file e309ade2-848e-3969-e053-3a05fe0a2c94
|
51
|
|
High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry, file e309ade2-8903-3969-e053-3a05fe0a2c94
|
50
|
|
Hematopoietic SCT in Europe 2013: Recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants, file e309ade2-8cd2-3969-e053-3a05fe0a2c94
|
49
|
|
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia, file e309ade2-9445-3969-e053-3a05fe0a2c94
|
49
|
|
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, file e309ade2-a1cc-3969-e053-3a05fe0a2c94
|
49
|
|
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry, file e309ade2-8484-3969-e053-3a05fe0a2c94
|
48
|
|
Issue highlights -May 2012, file e309ade2-87f5-3969-e053-3a05fe0a2c94
|
48
|
|
The Circular Life of Human CD38: From Basic Science to Clinics and Back, file e309ade2-c4d0-3969-e053-3a05fe0a2c94
|
48
|
|
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation, file e309ade2-a196-3969-e053-3a05fe0a2c94
|
47
|
|
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment, file e309ade4-0bc2-3969-e053-3a05fe0a2c94
|
47
|
|
Is allogeneic transplant for solid tumors still alive?, file e309ade2-8321-3969-e053-3a05fe0a2c94
|
46
|
|
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen, file e309ade2-885b-3969-e053-3a05fe0a2c94
|
46
|
|
Impact of drug development on the use of stem cell transplantation: A report by the European Society for Blood and Marrow Transplantation (EBMT), file e309ade2-8e86-3969-e053-3a05fe0a2c94
|
46
|
|
Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity, file e309ade2-b18a-3969-e053-3a05fe0a2c94
|
46
|
|
CD22 expression in b-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults, file e309ade2-81c4-3969-e053-3a05fe0a2c94
|
45
|
|
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: A retrospective study from the European Society for Blood and Marrow Transplantation database, file e309ade2-c9af-3969-e053-3a05fe0a2c94
|
45
|
|
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies, file e309ade3-cf84-3969-e053-3a05fe0a2c94
|
41
|
|
Multiparametric flow cytometric characterization of circulating stem cell subsets in patients with myocardial infarction: correlation with clinical and biological data, file e309ade4-3ab6-3969-e053-3a05fe0a2c94
|
41
|
|
Use of haploidentical stem cell transplantation continues to increase: The 2015 European Society for Blood and Marrow Transplant activity survey report, file e309ade2-d1f9-3969-e053-3a05fe0a2c94
|
39
|
|
Cotransplantation of mesenchymal cells and a higher relapse rate: a role for HLA-G molecules?, file e309ade0-2777-3969-e053-3a05fe0a2c94
|
37
|
|
Issue highlight–July 2018, file e309ade2-864f-3969-e053-3a05fe0a2c94
|
36
|
|
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi, file e309ade2-d1b8-3969-e053-3a05fe0a2c94
|
35
|
|
Development of adaptive immune effector therapies in solid tumors, file e309ade2-d2c3-3969-e053-3a05fe0a2c94
|
35
|
|
Is allogeneic transplant for solid tumors still alive?, file e309ade2-d1e8-3969-e053-3a05fe0a2c94
|
33
|
|
High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry, file e309ade2-c954-3969-e053-3a05fe0a2c94
|
32
|
|
Alloreactivity: the Janus-face of hematopoietic stem cell transplantation, file e309ade2-c9ba-3969-e053-3a05fe0a2c94
|
32
|
|
Issue highlight–July 2018, file e309ade2-d24d-3969-e053-3a05fe0a2c94
|
32
|
|
Hematopoietic stem cell transplantation in Europe 2014: More than 40 000 transplants annually, file e309ade2-c952-3969-e053-3a05fe0a2c94
|
29
|
|
Predicting failure of hematopoietic stem cell mobilization before it starts: The predicted poor mobilizer (pPM) score, file e309ade2-c9c3-3969-e053-3a05fe0a2c94
|
29
|
|
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen, file e309ade2-d1e9-3969-e053-3a05fe0a2c94
|
28
|
|
Predicting failure of hematopoietic stem cell mobilization before it starts: The predicted poor mobilizer (pPM) score, file e309ade2-c9c4-3969-e053-3a05fe0a2c94
|
25
|
|
Essential requirements for setting up a stem cell processing laboratory, file e309ade4-0a20-3969-e053-3a05fe0a2c94
|
25
|
|
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency, file e309ade4-1c86-3969-e053-3a05fe0a2c94
|
23
|
|
Sources and procurements of HSC, file e309ade2-958f-3969-e053-3a05fe0a2c94
|
21
|
|
Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity, file e309ade4-30e0-3969-e053-3a05fe0a2c94
|
17
|
|
Immunophenotypic heterogeneity of mesenchymal stromal cells: multiparametric flow cytometric analysis, file e309ade4-0e86-3969-e053-3a05fe0a2c94
|
14
|
|
Luigi Del Vecchio 1955-2018 In Memoriam, file e309ade2-c8c3-3969-e053-3a05fe0a2c94
|
13
|
|
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), file e309ade2-c93a-3969-e053-3a05fe0a2c94
|
12
|
|
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT), file e309ade2-c953-3969-e053-3a05fe0a2c94
|
12
|
|
The oldest case of lymphoma? Insights from a XIII century fresco, file 90d0d033-1e2e-45f5-9f20-e8f8b6ec10e8
|
9
|
|
Production of soluble HLA-G molecules by mesenchymal stromal cells after in vitro IL-10 activation: a marker for “a priori” evaluation of their immunoregulatory activity, file e309ade4-39f2-3969-e053-3a05fe0a2c94
|
9
|
|
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2015, file e309ade2-c8dc-3969-e053-3a05fe0a2c94
|
8
|
|
Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: A study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party, file e309ade4-62d6-3969-e053-3a05fe0a2c94
|
8
|
|
Potential clinical application of rhGM-CSF in acute myeloid leukemia based on its biological activity and receptor interaction, file e309ade2-a7cd-3969-e053-3a05fe0a2c94
|
7
|
|
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis, file e309ade4-422d-3969-e053-3a05fe0a2c94
|
7
|
|
COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey, file 5fe5d23f-652b-422c-a8a7-cc6b38b1ce21
|
6
|
|
Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012, file e309ade2-8e20-3969-e053-3a05fe0a2c94
|
6
|
|
Flow cytometry protocols, file e309ade2-970d-3969-e053-3a05fe0a2c94
|
6
|
| Totale |
11.032 |